All articles by Srivani Venna
Srivani Venna
PTC’s trial of sepiapterin for phenylketonuria achieves primary endpoint
Part 1 of the trial was a run-in phase, where all subjects who were screened received sepiapterin for two weeks.
First subjects in IBC’s Phase Ib trial receive IBC-Ab002
Patients with early Alzheimer’s disease will be randomised into a 3:1 ratio to receive IBC-Ab002 or placebo.
Arrowhead concludes enrolment for familial chylomicronemia syndrome trial
The primary portion of the trial is expected to be completed in the second quarter of next year.
First patient dosed in Inhibikase’s Phase II Parkinson’s disease trial
The primary endpoint of the study is to evaluate the safety, tolerability, and steady-state pharmacokinetics of IkT-148009.
Lynk’s RA therapy trial shows differences in efficacy against placebo
The subjects were randomised into LNK01001 high-dose, low-dose, and placebo groups at a ratio of 1:1:1.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
NewAmsterdam Pharma concludes subject enrolment in HeFH trial
The study participants were randomised to receive a placebo or 10mg obicetrapib dosed as a once-daily oral treatment.
Recruitment underway for Cambridge University’s coronavirus vaccine trials
DIOS-CoVax has already been part of trials that were conducted at the NIHR Southampton Clinical Research Facility.
IVERIC bio’s drug meets primary endpoint in geographic atrophy trials
The trials’ post-hoc analysis combined data showed a relationship between GA growth and worsening vision loss.
AbbVie reports positive results from trial of atogepant for migraine
The ELEVATE trial demonstrated reduction in MMDs for episodic migraine patients taking atogepant against a placebo.
Evecxia Therapeutics reports positive data from Phase I trial of EVX-101
All adverse events reported were mild or moderate, generally transient, and consistent with the serotonergic pharmacology.